Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $2.00 price target on the biotechnology company’s stock.

Separately, StockNews.com assumed coverage on Aptose Biosciences in a report on Friday, November 29th. They issued a “hold” rating for the company.

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO opened at $0.19 on Tuesday. The stock has a 50 day moving average price of $0.34 and a 200 day moving average price of $0.54. The stock has a market capitalization of $3.51 million, a PE ratio of -0.07 and a beta of 1.06. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.91.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.